Get the Stockscreener App
7.77
0.13%
0.010
After Hours:
7.77
Regenxbio Inc stock is traded at $7.77, with a volume of 619.60K.
It is up +0.13% in the last 24 hours and down -14.05% over the past month.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
See More
Previous Close:
$7.76
Open:
$7.752
24h Volume:
619.60K
Relative Volume:
0.65
Market Cap:
$401.03M
Revenue:
$170.44M
Net Income/Loss:
$-193.88M
P/E Ratio:
-2.0697
EPS:
-3.7541
Net Cash Flow:
$-126.38M
1W Performance:
-6.83%
1M Performance:
-14.05%
6M Performance:
-19.48%
1Y Performance:
-0.77%
1-Day Range:
$7.58
$7.885
1-Week Range:
$7.58
$8.78
52-Week Range:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.77 | 400.52M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
443.16 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.29 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
704.31 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.09 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.32 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
REGENXBIO Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Gene Therapy And US Patent Eligibility Update: REGENXBIO, Inc. v. Sarepta Therapeutics, Inc. - marketscreener.com
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 earnings call transcript - MSN
RGNX Stockholders Have Opportunity to Lead REGENXBIO Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Vanguard (RGNX) disaggregates holdings; reports 0 shares after realignment - Stock Titan
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO ... - Bluefield Daily Telegraph
RGNX Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
REGENXBIO Inc. $RGNX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. - GlobeNewswire
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - PR Newswire
RGNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD - finviz.com
Momentum Shift: Can REGENXBIO Inc deliver consistent dividendsEarnings Overview Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Panic Selling: Is REGENXBIO Inc impacted by rising ratesQuarterly Trade Review & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm - Sahm
Stop Loss: Is REGENXBIO Inc impacted by rising ratesWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP - Law360
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP - pharmiweb.com
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - ChartMill
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - FinancialContent
Patient centric approach drives AFFINITY DUCHENNE study expansion at REGENXBIO - Traders Union
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio says its gene therapy for muscle disorder showed no evidence of liver injury in study - MSN
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel ... - Caledonian Record
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: LEVI & KORSINSKY, LLP - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - Sahm
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGENXBIO Inc. $RGNX Shares Bought by JPMorgan Chase & Co. - MarketBeat
RGX-111 Security Concerns Approaching April 14 Cutoff: Legal Resolution or Trigger for Market Decline? - Bitget
REGENXBIO Inc. Files Form 8-K Announcing Material Definitive Agreement – Company Information and NASDAQ Listing Details - Minichart
Form 8K Regenxbio Inc For: 20 March By Investing.com - Investing.com Australia
Regenxbio reaches $10 million settlement with GlaxoSmithKline over sublicense fees - Investing.com
Form 8K Regenxbio Inc For: 20 March - Investing.com
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Regenxbio Inc has officially signed a settlement and release agreement with pharmaceutical giant GlaxoSmithKline. - Bitget
Regenxbio enters settlement and release agreement with GlaxoSmithKline on March 18, 2026SEC filing - marketscreener.com
According to a document submitted to the U.S. Securities and Exchange Commission, biotechnology company Regenxbio Inc has confirmed that it will continue, under its existing sublicensing agreement with pharmaceutical giant GlaxoSmithKline, to pay the l - Bitget
RegenXBio Reaches Settlement with GSK Over License Fees - TipRanks
Regenxbio Settles GSK Sublicense Fee Dispute With $10 Million Payment and Mutual Releases - TradingView
REGENXBIO (NASDAQ: RGNX) agrees $10M settlement payment to GSK - Stock Titan
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):